Jaguar Health Reports Increased Losses Amid Rising Expenses

Jaguar Animal Health Inc. ( (JAGX) ) has released its Q2 earnings. Here is a breakdown of the information Jaguar Animal Health Inc. presented to its investors.

Jaguar Health, Inc. is a pharmaceutical company based in San Francisco, California, focused on developing and commercializing prescription and non-prescription products for both human and animal health. The company operates through two segments: human health and animal health.

In its latest earnings report for the quarter ended June 30, 2025, Jaguar Health reported a net loss of $10.6 million, compared to a net loss of $9.6 million in the same period last year. The company generated total revenue of $2.98 million, a slight increase from $2.72 million in the previous year. The increase in revenue was primarily driven by product sales.

Key financial highlights include a decrease in cash reserves from $8 million at the end of 2024 to $2.2 million as of June 30, 2025. Operating expenses increased to $11 million from $9.9 million in the previous year, with significant spending on research and development and sales and marketing. The company also reported a negative cash flow from operations of $13.5 million for the first half of 2025.

Looking ahead, Jaguar Health’s management remains focused on its ongoing development and commercialization efforts, particularly in the human health segment with its subsidiary Napo Therapeutics. However, the company acknowledges the need for additional financing to support its operations and address its liquidity challenges.